Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | APL-4098 |
| Synonyms | |
| Therapy Description |
APL-4098 inhibits GCN2, which potentially results in decreased downstream signaling, increased antitumor immune response, and enhanced apoptosis in tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| APL-4098 | APL 4098|APL4098 | APL-4098 inhibits GCN2, which potentially results in decreased downstream signaling, increased antitumor immune response, and enhanced apoptosis in tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06372717 | Phase Ib/II | APL-4098 APL-4098 + Azacitidine | A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS | Recruiting | GBR | AUS | 0 |